nadifloxacin has been researched along with Exanthema in 2 studies
nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source
Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe exanthema (grade III/IV) develops in about 9-19 % of patients with the necessity of cetuximab dose reduction or cessation." | 1.39 | Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Herzog, J; Lang, H; Möhler, M; Schimanski, CC; Theobald, M; Wehler, TC, 2013) |
| "Characteristic papulopustular exanthemas, often described as acneiform rashes, are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of patients." | 1.38 | Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. ( Bölke, E; Budach, W; Buhren, BA; Eames, T; Ehmann, LM; Gerber, PA; Hetzer, S; Homey, B; Matuschek, C; Meller, S; Schrumpf, H; Wollenberg, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wehler, TC | 1 |
| Graf, C | 1 |
| Möhler, M | 1 |
| Herzog, J | 1 |
| Berger, MR | 1 |
| Gockel, I | 1 |
| Lang, H | 1 |
| Theobald, M | 1 |
| Galle, PR | 1 |
| Schimanski, CC | 1 |
| Gerber, PA | 1 |
| Meller, S | 1 |
| Eames, T | 1 |
| Buhren, BA | 1 |
| Schrumpf, H | 1 |
| Hetzer, S | 1 |
| Ehmann, LM | 1 |
| Budach, W | 1 |
| Bölke, E | 1 |
| Matuschek, C | 1 |
| Wollenberg, A | 1 |
| Homey, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors[NCT04864717] | Phase 4 | 98 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for nadifloxacin and Exanthema
| Article | Year |
|---|---|
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antibo | 2013 |
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.
Topics: Administration, Topical; ErbB Receptors; Exanthema; Fluoroquinolones; Humans; Isotretinoin; Mometaso | 2012 |